Please login to the form below

Not currently logged in
Email:
Password:

BCMA-targeting therapy

This page shows the latest BCMA-targeting therapy news and features for those working in and with pharma, biotech and healthcare.

bluebird bio to separate oncology and rare diseases units

bluebird bio to separate oncology and rare diseases units

Oncology Newco will assume responsibility for a number of bluebird bio’s current oncology assets, including its investigational BCMA-targeting CAR T therapy idecabtagene vicleucel (ide-cel), which is currently being ... In addition, Oncology Newco will

Latest news

  • Bluebird bio leans on pipeline and Zynteglo launch as revenues fall Bluebird bio leans on pipeline and Zynteglo launch as revenues fall

    Bluebird is in partnership with BMS for a BCMA-targeting cell therapy – bb2121 or ide-cel – which recently demonstrated positive top-line results in multiple myeloma. ... Aside from the mixed figures, bluebird is looking forward and focusing on the

  • FDA begins speedy review of BMS’ CAR-T liso-cel FDA begins speedy review of BMS’ CAR-T liso-cel

    or whose disease has relapsed,” said Stanley Frankel, senior vice president, cellular therapy development, BMS. ... In addition to liso-cel, BMS has another CAR-T therapy in the pipeline – its bluebird bio-partnered BCMA-targeting therapy bb2121 for

  • J&J and Bristol-Myers Squibb/Bluebird bio reveal rival CAR-T data J&J and Bristol-Myers Squibb/Bluebird bio reveal rival CAR-T data

    Both candidates are being studied in multiple myeloma. Johnson and Johnson and Bristol-Myers Squibb/Bluebird bio have both revealed data from their respective BCMA-targeting CAR-T therapies in multiple ... BMS/Bluebird also had their own CAR-T data in

  • GSK preps filings for BCMA-targeting multiple myeloma drug GSK preps filings for BCMA-targeting multiple myeloma drug

    GSK2857916 is one of a slew of BCMA-targeting therapies coming through the biopharma industry pipeline, jostling for position with a CAR-T therapy from Celgene and Bluebird Bio called bb2121 ... It is the most advanced BCMA-targeting ADC in development,

  • Europe urged to adapt faster to gene therapy challenges Europe urged to adapt faster to gene therapy challenges

    Meanwhile Bluebird is proposing a similar five-year instalment plan for its 1.57m beta thalassemia therapy Zynteglo. ... The next therapy area which could be transformed by cell therapy is multiple myeloma, where BCMA-targeting CAR-T therapies are in the

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics